

RENEWAL OF LICENSES ISSUED (continued):

Pasadena	Celanese Ltd.	L01130	Pasadena	78	10/26/17
San Angelo	Cardiology Associates of West Texas	L06102	San Angelo	04	10/24/17
San Antonio	VHS San Antonio Partners L.L.C. dba Baptist Health System	L00455	San Antonio	246	10/18/17
San Antonio	The University of Texas Health Science Center at San Antonio	L01279	San Antonio	165	10/24/17
San Antonio	Methodist Healthcare System of San Antonio Ltd., L.L.P.	L05076	San Antonio	36	10/20/17

TERMINATIONS OF LICENSES ISSUED:

Location of Use/Possession of Material	Name of Licensed Entity	License Number	City of Licensed Entity	Amendment Number	Date of Action
Conroe	Arif Abdullah M.D., P.A.	L06276	Conroe	05	10/16/17
El Paso	El Paso Heart Center	L04828	El Paso	21	10/19/17
Throughout TX	Streamline Production Systems Inc.	L06658	Kountze	04	10/31/17
Tomball	Tomball Texas Hospital Company L.L.C. dba Tomball Regional Medical Center	L06472	Tomball	12	10/20/17

TRD-201704722
Barbara L. Klein
Interim General Counsel
Department of State Health Services
Filed: November 20, 2017

*naldemedine, naloxegol, naloxone and its salts, naltrexone and its salts, and nalmefene and its salts, but including:

Changes to the schedules are marked with an asterisk (*).

TRD-201704782
Barbara L. Klein
Interim General Counsel
Department of State Health Services
Filed: November 22, 2017

Order Removing Naldemedine from Schedule II Substances

The Administrator of the Drug Enforcement Administration issued a final order removing the substance naldemedine and its salts from schedule II of the Controlled Substances Act effective September 29, 2017. This final order was published in the September 29, 2017 *Federal Register*, Volume 82, Number 188, pages 45436-45438. After taking into consideration the substance's abuse potential, legitimate medical use, and dependence liability, the Administrator has determined that naldemedine does not meet the requirements for inclusion in any schedule.

Pursuant to Health and Safety Code, §481.034(g), as amended by the 75th Legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced action was published in the *Federal Register*; and, in the capacity as Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that the substance naldemedine be removed from the Schedule II substances.

SCHEDULE II

Schedule II consists of:

-Schedule II substances, vegetable origin or chemical synthesis

The following substances, however produced, except those narcotic drugs listed in other schedules:

(1) Opium and opiate, and a salt, compound, derivative, or preparation of opium or opiate, other than thebaine-derived butorphanol,

Texas Health and Human Services Commission

Notice of Public Hearing on Proposed Medicaid Payment Rates for the Residential Care Program, Assisted Living Services, and Personal Care 3 Services

Hearing. The Texas Health and Human Services Commission (HHSC) will conduct a public hearing on January 3, 2018, at 9:00 a.m., to receive comment on proposed Medicaid payment rates for the Residential Care (RC) Program, Assisted Living (AL) services, and Personal Care 3 (PC3) services. The proposed rates for the RC program will be utilized in the fee-for-service payment model and the proposed rates for AL and PC3 services will be utilized in the calculation of the STAR+PLUS managed care capitation rates for the Home and Community-Based Services risk group.

The public hearing will be held in the Public Hearing Room of the Brown-Heatly Building located at 4900 N. Lamar Boulevard, Austin, Texas. Entry is through Security at the main entrance of the building, which faces Lamar Boulevard. HHSC will also broadcast the public hearing; the broadcast can be accessed at <https://hhs.texas.gov/about-hhs/communications-events/live-archived-meetings>. The broadcast will be archived and can be accessed on demand at the same website. The hearing will be held in compliance with Texas Human Resources Code §32.0282, which requires public notice of and hearings on proposed Medicaid reimbursements.